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René Descartes University, Paris, France, 5Real World Evidence/Global Clinical
Outcomes, Sanofi US, Cambridge, MA, USA, 6Biostatistics, Sanofi, Chilly-Mazarin,
France, 7Global Medical Oncology, Sanofi US, Cambridge, MA, USA, 8The Sidney
Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA,
9Division of Clinical Studies Drug Development Unit, Royal Marsden NHS Foundation
Trust/The Institute of Cancer Research, Sutton, UK
Background: PROSELICA (NCT01308580) assessed the non-inferiority of cabazitaxel
20 mg/m2 (C20) vs 25 mg/m2 (C25) in patients (pts) with mCRPC post docetaxel, while
FIRSTANA (NCT01308567) investigated whether C20 and C25 were superior to doce-
taxel 75 mg/m2 (D75) in chemotherapy-naive mCRPC. This analysis evaluated the
impact of cabazitaxel on HRQL in both trials.
Methods: Alongside pain and analgesic score, HRQL was assessed using the Functional
Assessment of Cancer Therapy Prostate (FACT-P) questionnaire. The analysis focused
on FACT-P (clinically meaningful improvement or deterioration of total score [TS])
among responders.
Results: Pt baseline characteristics are shown in the table. In PROSELICA, 57.2% and
59.4% of pts receiving C20 and C25 had FACT-P TS improvements; in FIRSTANA,
63.5%, 62.3% and 57.7% of pts receiving C20, C25 and D75 had FACT-P TS improve-
ments. In FACT-P responders, FACT-P TS improvements occurred as early as Cycle
(C) 1 (mean change from baseline: PROSELICA C20 10.4, n¼ 264; C25 10.6, n¼ 266;
FIRSTANA C20 11.7, n¼ 206; C25 11.7, n¼ 202; D75 9.0, n¼ 195); these were largely
maintained. For pts with a pain response in PROSELICA, FACT-P TS improvements
occurred as early as C1 (C20 6.8, n¼ 71; C25 11.1, n¼ 81) and were maintained until
C8 (C20 10.6, n¼ 43; C25 9.6, n¼ 44). In FIRSTANA, FACT-P TS improvements in
pts with a pain response were seen as early as C1 or C2 (C1: C20 15.5, n¼ 41; C25 12.5,
n¼ 41; D75, 7.9, n¼ 32) and maintained until C9 (C20 9.0, n¼ 27; C25 10.5, n¼ 26;
D75 16.4, n¼ 20). In pts with a tumor or PSA response, HRQL was maintained for all
treatment arms in both studies. Additional results for clinical responder subgroups and
FACT-P subscales will be presented.
Conclusions: More than half of the pts experienced HRQL improvements, which were
maintained. Pts with a pain response experienced HRQL improvements. Funding:
Sanofi.
Clinical trial identification: PROSELICA: NCT01308580. FIRSTANA: NCT01308567.
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Background: The usual sequence of progression events in mCRPC patients treated
with new hormonal agents is known: PSA progression, followed by radiological pro-
gression and finally pain progression (Ryan, NEJM 2013; Beer, NEJM 2014). Although
pain was associated with poor overall survival (OS) in the TAX 327 (Berthold, Clin
Cancer Res 2008) and CALGB trials (Halabi, JCO 2008), the influence of type of pro-
gression on outcomes is not well documented in phase III trials with chemotherapy.
Here, we investigated the impact of type of progression on OS in mCRPC patients
receiving docetaxel-based chemotherapy.
Methods: Data from the phase III study VENICE evaluating docetaxel 75mg/m2 q3w 6
aflibercept (Tannock, Lancet Oncol 2013) was used as a training dataset. At randomiza-
tion, group 1 (G1) had PSA progression only (n¼ 231), G2 had radiological progres-
sion (6 PSA) but no pain (n¼ 348), and G3 had pain (6 PSA, 6 radiological)
(n¼ 447). The TAX327 definition for pain was used: Mean present pain intensity 2
and/or mean analgesic score 10 within 7 days prior to randomization (Tannock,
NEJM 2004). The impact of type of progression on OS was evaluated in a multivariate
Cox regression analysis with backward elimination (5% level), stratified for ECOG per-
formance status (0-1 vs 2) and treatment arm.
Results: In the VENICE trial median OS was 28.6 months for G1, 26.3 months for G2
and 16.9 months for G3. Hazard ratios [95% CI] for death were 1.14 [0.92-1.41] in G2
Table: 812P
Baseline characteristics FIRSTANA PROSELICA
D75 (n¼ 391) C20 (n¼ 389) C25 (n¼ 388) C20 (n¼ 598) C25 (n¼ 602)
Median age, years (range) 69.0 (41–87) 68.0 (44–90) 68.5 (42–85) 68.0 (45–89) 69.0 (45–88)
ECOG PS, n (%)
0–1 374 (95.7) 370 (95.1) 376 (96.9) 539 (90.1) 540 (89.7)
2 17 (4.3) 19 (4.9) 12 (3.1) 59 (9.9) 62 (10.3)
Mean PSA, ng/mL (SD) 252.8 (625.2) 213.2 (434.2) 257.9 (578.8) 451.5 (881.0) 444.0 (834.0)
Median present pain intensity, score (range) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–5.0) 2.0 (0.0–5.0)
Median FACT-P TS (range) 107.4 (41.1–152.0) 107.1 (47.2–151.0) 105.7 (40.1–148.8) 102.8 (37.0–152.8) 101.6 (33.9–150.9)
C20, cabazitaxel 20 mg/m2; C25, cabazitaxel 25 mg/m2; D75, docetaxel 75 mg/m2; ECOG PS, Eastern Cooperative Oncology Group Performance Status;
FACT-P TS, Functional Assessment of Cancer Therapy Prostate Total Score; PSA, prostate-specific antigen; SD, standard deviation.
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and 2.13 [1.75 - 2.59] in G3 compared to G1. In multivariate analysis, pain at random-
ization was the strongest predictor of poor OS: HR 1.71, 95% CI 1.39-2.11, vs PSA pro-
gression only. Other significant prognostic factors included older age, high alkaline
phosphatase, short duration of first androgen deprivation therapy, low hemoglobin
level and high neutrophil-lymphocyte ratio. Docetaxel led to 50% decline in PSA in
67.5%, 80.5% and 77% in G1, G2 and G3 respectively.
Conclusions: The type of progression at initiation of first-line chemotherapy in
mCRPC is prognostic. Patients with pain at initiation of chemotherapy had a median
OS of1 year shorter than those having PSA progression only. Validation of these
results by an independent dataset (TAX 327) is ongoing. Results will be presented at
ESMO.
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Background: Platinum compounds have been tested in a larger number of mostly small
to medium sized clinical trials in molecularly unselected prostate cancer patients (pts).
Advances in castration-resistant prostate cancer (CRPC) molecular profiling have
shown that a significant proportion of pts harbor DNA repair defects, which may serve
as predictive markers for sensitivity to platinum agents. Our aim was to evaluate the
antitumour activity of platinum agents in a contemporaneous mCRPC cohort with or
without DNA repair defects.
Methods: International, multicenter retrospective database project in 14 centers world-
wide. Pts with mCRPC treated with a platinum agent were included. Pts with primary
pure small cell carcinoma and/or insufficient outcome data were excluded. For antitu-
mour activity PSA levels at baseline, after 4-, 8- and 12-weeks of therapy (tx) were ana-
lyzed as well as soft tissue response and duration of platinum-based chemotherapy.
Overall survival (OS) was analyzed by Kaplan Meier method.
Results: A total of 167 pts have been included in this analysis, 33 (20%) received plati-
num monotherapy, 134 (80%) a platinum combination therapy. Carboplatin was used
in 140 (84%), cisplatin in 26 (16%) of pts. Combination tx with etoposise was used in
45 (27%), paclitaxel in 35 (21%) and docetaxel in 28 (17%) of pts. At start of platinum
tx median age was 68 years, median PSA 78 ug/l, median ALP 185 U/l, median hemo-
globin 103 g/l. The metastatic sites at start of platinum therapy were: bone 84%, lymph
node 59% and visceral 60%. Outcome data by DNA repair defect status are summar-


















N (%) N (%) N (%)
PSA decline 50% 13/32 (41) 8/23 (35) 24/73 (33)
Soft tissue response (PR/CR) 9/32 (28) 7/29 (24) 16/48 (33)
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Conclusions: In this retrospective analysis of a contemporary cohort of men with
mCRPC and poor prognostic characteristics platinum-based treatment seems to have
significant anti-tumor activity irrespective of DNA repair status. Comparison of sub-
groups is limited by small sample size. Updated analyses will be presented.
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Background: Bone metastases are common in CRPC patients and these patients (pts)
are at risk for symptomatic skeletal related events (SSE). Bone directed therapy and
early initation of a life-prolonging drug (LPD) therapy can prevent or prolong time to
SSEs. The objective is to evaluate whether delay in LPD has adverse outcome in CRPC
pts and a shorter SSE-free interval.
Methods: CAPRI is an investigator-initiated, observational study in 20 hospitals in the
Netherlands. All treated CRPC pts are retrospectively included in subgroups based on
type of first line treatment: LPD (docetaxel, abiraterone, enzalutamide or radium-223)
or non-LPD (other drugs as anti-androgens, prednisone). SSEs are defined as the
occurrence of either radiotherapy (RT) to the bone, surgery to the bone, pathological
fracture or spinal cord compression (SCC).
Results: 1,618 pts were included in this analysis. Median follow-up was 26 months
(IQR 15-39). 466 (29%) were treated with LPD (mostly docetaxel 15%) and 1,152
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